Of Mice and Men-Warning: Intact Versus Castrated Adult Male Mice as Xenograft Hosts Are Equivalent to Hypogonadal Versus Abiraterone Treated Aging Human Males, Respectively

por Sedelaar, J.P. Michiel, Dalrymple, Susan S., Isaacs, John T.
Publicado 2013

Androgen Receptor (AR) Suppresses Normal Human Prostate Epithelial Cell Proliferation via AR/β-catenin/TCF-4 Complex Inhibition of c-MYC Transcription

por Antony, Lizamma, van der Schoor, Freek, Dalrymple, Susan L., Isaacs, John T.
Publicado en Prostate (2014)

Tasquinimod Prevents the Angiogenic Rebound Induced by Fractionated Radiation Resulting in an Enhanced Therapeutic Response of Prostate Cancer Xenografts

por Dalrymple, Susan L., Becker, Robyn E., Zhou, Haoming, DeWeese, Theodore L., Isaacs, John T.
Publicado 2011

Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment

por Isaacs, John T., Dalrymple, Susan L., Rosen, D. Marc, Hammers, Hans, Olsson, Anders, Leanderson, Tomas
Publicado en Oncotarget (2014)

Low-Calcium Serum-Free Defined Medium Selects for Growth of Normal Prostatic Epithelial Stem Cells

por Litvinov, Ivan V., Vander Griend, Donald J., Xu, Yi, Antony, Lizamma, Dalrymple, Susan L., Isaacs, John T.
Publicado 2006

The Role of CD133 in Normal Human Prostate Stem Cells and Malignant Cancer-Initiating Cells

por Vander Griend, Donald J., Karthaus, Wouter L., Dalrymple, Susan, Meeker, Alan, DeMarzo, Angelo M., Isaacs, John T.
Publicado 2008

Assessing angiogenic responses induced by primary human prostate stromal cells in a three-dimensional fibrin matrix assay

por Brennen, W. Nathaniel, Nguyen, Huong, Dalrymple, Susan L., Reppert-Gerber, Stephanie, Kim, Jeesun, Isaacs, John T., Hammers, Hans
Publicado en Oncotarget (2016)

Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells

por Vander Griend, Donald J., Antony, Lizamma, Dalrymple, Susan L., Xu, Yi, Christensen, S. Brogger, Denmeade, Samuel R., Isaacs, John T.
Publicado 2009

Loss of Androgen Receptor-Dependent Growth Suppression by Prostate Cancer Cells Can Occur Independently from Acquiring Oncogenic Addiction to Androgen Receptor Signaling

por D'Antonio, Jason M., Vander Griend, Donald J., Antony, Lizamma, Ndikuyeze, George, Dalrymple, Susan L., Koochekpour, Shahriar, Isaacs, John T.
Publicado 2010

Androgen Withdrawal Fails to Induce Detectable Tissue Hypoxia in the Rat Prostate

por Regter, Sietze, Hedayati, Mohammad, Zhang, Yonggang, Zhou, Haoming, Dalrymple, Susan, Koch, Cameron J., Isaacs, John T., DeWeese, Theodore L.
Publicado en Prostate (2014)

Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells

por Litvinov, Ivan V., Vander Griend, Donald J., Antony, Lizamma, Dalrymple, Susan, De Marzo, Angelo M., Drake, Charles G., Isaacs, John T.
Publicado 2006

Adaptive Auto-Regulation of Androgen Receptor Provides a Paradigm Shifting Rationale for Bipolar Androgen Therapy (BAT) for Castrate Resistant Human Prostate Cancer

por Isaacs, John T., D’Antonio, Jason M., Chen, Shuangling, Antony, Lizamma, Dalrymple, Susan P., Ndikuyeze, Georges H., Luo, Jun, Denmeade, Samuel R.
Publicado 2012

Tasquinimod is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment

por Isaacs, John T, Antony, Lizamma, Dalrymple, Susan L, Brennen, W. Nathaniel, Gerber, Stephanie, Hammers, Hans, Wissing, Michel, Kachhap, Sushant, Luo, Jun, Xing, Li, Björk, Per, Olsson, Anders, Björk, Anders, Leanderson, Tomas
Publicado 2012

Role of androgen receptor splice variant 7 (AR-V7) in prostate cancer resistance to 2(nd) generation androgen receptor signaling inhibitors

por Zhu, Yezi, Dalrymple, Susan L., Coleman, Ilsa, Zheng, S. Lilly, Xu, Jianfeng, Hooper, Jody E., Antonarakis, Emmanuel S., De Marzo, Angelo M., Meeker, Alan K., Nelson, Peter S., Isaacs, William B., Denmeade, Samuel R., Luo, Jun, Brennen, W. Nathaniel, Isaacs, John T.
Publicado en Oncogene (2020)

Androgen deprivation followed by acute androgen stimulation selectively sensitizes AR-positive prostate cancer cells to ionizing radiation

por Hedayati, Mohammad, Haffner, Michael C., Coulter, Jonathan B., Raval, Raju R., Zhang, Yonggang, Zhou, Haoming, Mian, Omar, Knight, Emma J., Razavi, Nina, Dalrymple, Susan, Isaacs, John T., Santos, Aileen, Hales, Russell, Nelson, William G., Yegnasubramanian, Srinivasan, DeWeese, Theodore L.
Publicado en Clin Cancer Res (2016)

Engineering a Prostate-Specific Membrane Antigen–Activated Tumor Endothelial Cell Prodrug for Cancer Therapy

por Denmeade, Samuel R., Mhaka, Annastasiah M., Rosen, D. Marc, Brennen, W. Nathaniel, Dalrymple, Susan, Dach, Ingrid, Olesen, Claus, Gurel, Bora, DeMarzo, Angelo M., Wilding, George, Carducci, Michael A., Dionne, Craig A., Møller, Jesper V., Nissen, Poul, Christensen, S. Brøgger, Isaacs, John T.
Publicado 2012

Microparticle Encapsulation of a Prostate-Targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-Resistant Prostate Cancer

por Rogers, Oliver C., Antony, Lizamma, Levy, Oren, Joshi, Nitin, Simons, Brian W., Dalrymple, Susan L., Rosen, D. Marc, Pickering, Andrew, Lan, Haoyue, Kuang, Heidi, Ranganath, Sudhir, Zheng, Lei, Karp, Jeffrey M., Howard, S. Peter, Denmeade, Samuel R., Isaacs, John T., Brennen, W. Nathaniel
Publicado en Mol Cancer Ther (2020)

Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer

por Brennen, W. Nathaniel, Zhu, Yezi, Coleman, Ilsa M., Dalrymple, Susan L., Antony, Lizamma, Patel, Radhika A., Hanratty, Brian, Chikarmane, Roshan, Meeker, Alan K., Zheng, S. Lilly, Hooper, Jody E., Luo, Jun, De Marzo, Angelo M., Corey, Eva, Xu, Jianfeng, Yegnasubramanian, Srinivasan, Haffner, Michael C., Nelson, Peter S., Nelson, William G., Isaacs, William B., Isaacs, John T.
Publicado en JCI Insight (2021)